JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms

British Journal of Haematology

Volumn 169, Issue 6, 2015, Pages 824-833

  Parampalli Yajnanarayana, Sowmya ^a   Stübig, Thomas ^b   Cornez, Isabelle ^a   Alchalby, Haefaa ^b   Schönberg, Kathrin ^a   Rudolph, Janna ^a   Triviai, Ioanna ^b   Wolschke, Christine ^b   Heine, Annkristin ^a   Brossart, Peter ^a   Kröger, Nicolaus ^b   Wolf, Dominik ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Immunotherapy; Janus kinases inhibitor; Myeloproliferative disease; Ruxolitinib; T cells

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; RUXOLITINIB; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; STAT5 PROTEIN;

ADULT; AGED; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE FUNCTION; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TH17 CELL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFECTS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION;

AGED; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; HUMANS; IMMUNOPHENOTYPING; JANUS KINASE 1; JANUS KINASE 2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PROTEIN KINASE INHIBITORS; PYRAZOLES; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84930257399     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13373     Document Type: Article

References (32)

1. + T cells. Nature Immunology, 3, 549-557.
2. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R.; Cancer Genome Project. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054-1061.
3. Burchill, M.A., Yang, J., Vogtenhuber, C., Blazar, B.R. & Farrar, M.A. (2007) IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. Journal of Immunology (Baltimore, Md.: 1950), 178, 280-290.
4. Cervantes, F., Vannucchi, A.M., Kiladjian, J.-J., Al-Ali, H.K., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R.S., Passamonti, F., Barbui, T., Barosi, G., Harrison, C.N., Knoops, L. & Gisslinger, H.; COMFORT-II investigators. (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 122, 4047-4053.
5. Cornez, I., Joel, M., Taskén, K., Langmoen, I.A., Glover, J.C. & Berge, T. (2013) EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry. Journal of Neuro-Oncology, 112, 49-57.
6. El Kasmi, K.C., Holst, J., Coffre, M., Mielke, L., de Pauw, A., Lhocine, N., Smith, A.M., Rutschman, R., Kaushal, D., Shen, Y., Suda, T., Donnelly, R.P., Myers, M.G., Alexander, W., Vignali, D.A.A., Watowich, S.S., Ernst, M., Hilton, D.J. & Murray, P.J. (2006) General nature of the STAT3-activated anti-inflammatory response. Journal of Immunology (Baltimore, Md.: 1950), 177, 7880-7888.
7. Fridman, J.S., Scherle, P.A., Collins, R., Burn, T., Neilan, C.L., Hertel, D., Contel, N., Haley, P., Thomas, B., Shi, J., Collier, P., Rodgers, J.D., Shepard, S., Metcalf, B., Hollis, G., Newton, R.C., Yeleswaram, S., Friedman, S.M. & Vaddi, K. (2011) Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. The Journal of Investigative Dermatology, 131, 1838-1844.
8. Harris, T.J., Grosso, J.F., Yen, H.-R., Xin, H., Kortylewski, M., Albesiano, E., Hipkiss, E.L., Getnet, D., Goldberg, M.V., Maris, C.H., Housseau, F., Yu, H., Pardoll, D.M. & Drake, C.G. (2007) Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. Journal of Immunology (Baltimore, Md.: 1950), 179, 4313-4317.
9. Harrison, C., Kiladjian, J.-J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. & Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine, 366, 787-798.
10. Heine, A., Held, S.A.E., Daecke, S.N., Wallner, S., Yajnanarayana, S.P., Kurts, C., Wolf, D. & Brossart, P. (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood, 122, 1192-1202.
11. Hornung, T., Janzen, V., Wenzel, J., Heidgen, F.-J., Wolf, D. & Bieber, T. (2014) Remission of recalcitrant dermatomyositis treated with ruxolitinib. The New England Journal of Medicine, 371, 2537-2538.
12. Karaghiosoff, M., Neubauer, H., Lassnig, C., Kovarik, P., Schindler, H., Pircher, H., McCoy, B., Bogdan, C., Decker, T., Brem, G., Pfeffer, K. & Müller, M. (2000) Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity, 13, 549-560.
13. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.-S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine, 352, 1779-1790.
14. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J.P., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Fröhling, S., Döhner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387-397.
15. Manel, N., Unutmaz, D. & Littman, D.R. (2008) The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nature Immunology, 9, 641-649.
16. Massa, M., Rosti, V., Campanelli, R., Fois, G. & Barosi, G. (2014) Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia, 28, 449-451.
17. Parham, C., Chirica, M., Timans, J., Vaisberg, E., Travis, M., Cheung, J., Pflanz, S., Zhang, R., Singh, K.P., Vega, F., To, W., Wagner, J., O'Farrell, A.-M., McClanahan, T., Zurawski, S., Hannum, C., Gorman, D., Rennick, D.M., Kastelein, R.A., de Waal Malefyt, R. & Moore, K.W. (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. Journal of Immunology (Baltimore, Md.: 1950), 168, 5699-5708.
18. Passamonti, F., Maffioli, M., Cervantes, F., Vannucchi, A.M., Morra, E., Barbui, T., Caramazza, D., Pieri, L., Rumi, E., Gisslinger, H., Knoops, L., Kiladjian, J.J., Mora, B., Hollaender, N., Pascutto, C., Harrison, C. & Cazzola, M. (2014) Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood, 123, 1833-1835.
19. Pattison, M.J., Mackenzie, K.F. & Arthur, J.S.C. (2012) Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. Journal of Immunology (Baltimore, Md.: 1950), 189, 2784-2792.
20. Percy, M.J. & McMullin, M.F. (2005) The V617F JAK2 mutation and the myeloproliferative disorders. Hematological Oncology, 23, 91-93.
21. Schindler, C., Levy, D.E. & Decker, T. (2007) JAK-STAT signaling: from interferons to cytokines. The Journal of Biological Chemistry, 282, 20059-20063.
22. Spoerl, S., Mathew, N.R., Bscheider, M., Schmitt-Graeff, A., Chen, S., Mueller, T., Verbeek, M., Fischer, J., Otten, V., Schmickl, M., Maas-Bauer, K., Finke, J., Peschel, C., Duyster, J., Poeck, H., Zeiser, R. & von Bubnoff, N. (2014) Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood, 123, 3832-3842.
23. Stahl, N., Boulton, T.G., Farruggella, T., Ip, N.Y., Davis, S., Witthuhn, B.A., Quelle, F.W., Silvennoinen, O., Barbieri, G. & Pellegrini, S. (1994) Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science (New York, N.Y.), 263, 92-95.
24. Tefferi, A. (2000) Myelofibrosis with myeloid metaplasia. The New England Journal of Medicine, 342, 1255-1265.
25. Tefferi, A. & Pardanani, A. (2011) Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clinic Proceedings, 86, 1188-1191.
26. Verstovsek, S., Kantarjian, H., Mesa, R.A., Pardanani, A.D., Cortes-Franco, J., Thomas, D.A., Estrov, Z., Fridman, J.S., Bradley, E.C., Erickson-Viitanen, S., Vaddi, K., Levy, R. & Tefferi, A. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. The New England Journal of Medicine, 363, 1117-1127.
27. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M.W.N., Miller, C.B., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H., Arcasoy, M.O., Hexner, E.O., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Sun, W., Sandor, V. & Kantarjian, H.M. (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica, 98, 1865-1871.
28. Williams, L.M., Sarma, U., Willets, K., Smallie, T., Brennan, F. & Foxwell, B.M.J. (2007) Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. The Journal of Biological Chemistry, 282, 6965-6975.
29. Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S.B. & Zhao, Z.J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. The Journal of Biological Chemistry, 280, 22788-22792.
30. Zhou, T., Georgeon, S., Moser, R., Moore, D.J., Caflisch, A. & Hantschel, O. (2014) Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia, 28, 404-407.
31. Zhu, J. & Paul, W.E. (2008) CD4 T cells: fates, functions, and faults. Blood, 112, 1557-1569.
32. Zhu, J., Yamane, H. & Paul, W.E. (2010) Differentiation of effector CD4 T cell populations (*). Annual Review of Immunology, 28, 445-489.